Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.31 |
| ▸ | BRD1 | O95696 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297466 | 0.89 | HSD11B1 (0.34) | HSD11B1HTR6DGAT1 | |
| SCHEMBL3304808 | 0.88 | IRAK4 (0.34) | BRPF1BRD1IRAK4 | |
| SCHEMBL3297421 | 0.85 | LMNA (0.33) | HSD11B1HTR6IRAK4DGAT1 | |
| SCHEMBL3300116 | 0.85 | IRAK4 (0.37) | BRPF1BRD1IRAK4DGAT1 | |
| SCHEMBL3298556 | 0.85 | CDC7 (0.36) | CCR9BRPF1BRD1IRAK4 | |
| SCHEMBL3300103 | 0.84 | KMT2A (0.32) | HSD11B1BRPF1BRD1HTR6 | |
| SCHEMBL3299456 | 0.83 | BRD1 (0.30) | HSD11B1BRPF1BRD1 | |
| SCHEMBL3298498 | 0.83 | — | — | |
| SCHEMBL3298307 | 0.82 | HSD11B1 (0.32) | HSD11B1HTR6DGAT1 | |
| SCHEMBL3303632 | 0.82 | ROCK1 (0.34) | HSD11B1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | CCR9 4171/4885CTSS 3111/4885HSD11B1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.